Reconsideration of the Benefits of Pharmacological Interventions for the Attenuation of the Cognitive Adverse Effects of Electroconvulsive Therapy.
Journal
The Journal of clinical psychiatry
ISSN: 1555-2101
Titre abrégé: J Clin Psychiatry
Pays: United States
ID NLM: 7801243
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
The cognitive adverse effects (AEs) of electroconvulsive therapy (ECT) limit the wider use of the treatment. These AEs can be attenuated by changing the way ECT is administered; however, such changes may reduce the response rate, the speed of response, or both. A recent systematic review and meta-analysis identified more than a dozen pharmacologic interventions in 26 randomized controlled trials (RCTs) that sought to reduce ECT-induced cognitive AEs. Because of large differences across RCTs, only a few outcomes for a few interventions could be pooled in meta-analysis, and most pooled analyses included only 2-3 RCTs. Important findings were that acetylcholinesterase inhibitors, ketamine, memantine, and liothyronine were associated with improved global cognitive functioning at 1-14 days post-ECT. Anti-inflammatory treatments and opioid receptor antagonists were not associated with improvement in general cognitive outcome at 1-14 days post-ECT. Meta-analysis was not possible for the remaining interventions, including piracetam, melatonin, pemoline, nortriptyline, herbal agents, drugs acting on the cortisol pathway, opioid receptor antagonists, l-tryptophan, vasopressin analogs, calcium channel blockers, and others; in individual RCTs, some of these interventions attenuated some cognitive measures as some time points after ECT. Regrettably, none of the RCTs examined clinically meaningful outcomes such as subjective cognitive impairment, impairments in daily life, and persistent autobiographical memory deficits. Future research should study such clinically meaningful outcomes (rather than laboratory tests), using pharmacologic interventions, perhaps in combination, for ECT procedures that are associated with higher cognitive AE burden. A risk is that whatever attenuates ECT-induced cognitive AEs may also attenuate ECT-related therapeutic benefits.
Identifiants
pubmed: 36198062
doi: 10.4088/JCP.22f14668
doi:
pii:
Substances chimiques
Calcium Channel Blockers
0
Cholinesterase Inhibitors
0
Narcotic Antagonists
0
Triiodothyronine
06LU7C9H1V
Ketamine
690G0D6V8H
Pemoline
7GAQ2332NK
Tryptophan
8DUH1N11BX
Nortriptyline
BL03SY4LXB
Melatonin
JL5DK93RCL
Memantine
W8O17SJF3T
Hydrocortisone
WI4X0X7BPJ
Piracetam
ZH516LNZ10
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Copyright 2022 Physicians Postgraduate Press, Inc.